Literature DB >> 25952960

Tremor-related quality of life: A comparison of essential tremor vs. Parkinson's disease patients.

Elan D Louis1, Duarte G Machado2.   

Abstract

BACKGROUND: Tremor-related quality of life is a multi-dimensional concept that reflects the physical, emotional and other health effects of tremor. Curiously, tremor-related quality of life has never been directly compared in patients with the two major tremor disorders, essential tremor (ET) and Parkinson's disease (PD). We performed a head-to-head comparison of ET with PD patients.
METHODS: The Quality of Life in Essential Tremor (QUEST) questionnaire was administered to 103 ET and 103 matched PD patients enrolled in a clinical-epidemiological study in New York.
RESULTS: The QUEST total score and QUEST physical subscore were higher in ET than PD patients (both p < 0.05). In relative terms, ET patients reported significantly more impairment than PD patients in multiple areas; PD patients reported more impairment than ET patients in one area (all p ≤ 0.02). In absolute terms, tremor impacted on many aspects of quality of life in both diseases, including physical and psychosocial, and in one-third or more of PD patients, tremor sometimes, frequently or always interfered with numerous physical activities, including writing, using a typewriter/computer, fixing small things, dressing, eating, and holding reading material.
CONCLUSIONS: Tremor is a clinical entity that can have numerous effects on patients. While there were relative differences between the two major tremor disorders, ET and PD, in absolute terms, tremor impacted on several domains of quality of life, from physical to psychosocial, in a large proportion of ET and PD patients. Attempts to judge the efficacy of treatments for tremor, whether pharmacological or surgical, should consider its broad impact.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical; Essential tremor; Parkinson's disease; Quality of life; Tremor

Mesh:

Year:  2015        PMID: 25952960      PMCID: PMC4764063          DOI: 10.1016/j.parkreldis.2015.04.019

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  26 in total

1.  Development of an essential tremor embarrassment assessment.

Authors:  Rebecca E Traub; Marina Gerbin; Mary M Mullaney; Elan D Louis
Journal:  Parkinsonism Relat Disord       Date:  2010-09-24       Impact factor: 4.891

2.  Depressive traits in essential tremor: impact on disability, quality of life, and medication adherence.

Authors:  E D Louis; E D Huey; M Gerbin; A S Viner
Journal:  Eur J Neurol       Date:  2012-05-29       Impact factor: 6.089

3.  Quality of life and its determinants in essential tremor.

Authors:  Vijay Chandran; Pramod Kumar Pal
Journal:  Parkinsonism Relat Disord       Date:  2012-07-05       Impact factor: 4.891

4.  Quality of life following DBS in the caudal zona incerta in patients with essential tremor.

Authors:  Ulrika Sandvik; Gun-Marie Hariz; Patric Blomstedt
Journal:  Acta Neurochir (Wien)       Date:  2011-11-23       Impact factor: 2.216

5.  The relation of falls to fatigue, depression and daytime sleepiness in Parkinson's disease.

Authors:  M S Bryant; D H Rintala; J G Hou; S P Rivas; A L Fernandez; E C Lai; E J Protas
Journal:  Eur Neurol       Date:  2012-05-03       Impact factor: 1.710

6.  Estimating annual rate of decline: prospective, longitudinal data on arm tremor severity in two groups of essential tremor cases.

Authors:  Elan D Louis; Angus Agnew; Arthur Gillman; Marina Gerbin; Amanda S Viner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-03-24       Impact factor: 10.154

7.  Most of the Quality of Life in Essential Tremor Questionnaire (QUEST) psychometric properties resulted in satisfactory values.

Authors:  Pablo Martínez-Martín; Félix Javier Jiménez-Jiménez; Esmeralda Carroza García; Hortensia Alonso-Navarro; Lluisa Rubio; Patricia Calleja; María Díaz-Sánchez; Julián Benito-León
Journal:  J Clin Epidemiol       Date:  2009-12-02       Impact factor: 6.437

8.  Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial.

Authors:  Joseph M Ferrara; Christopher Kenney; Anthony L Davidson; Lina Shinawi; Abigail M Kissel; Joseph Jankovic
Journal:  J Neurol Sci       Date:  2009-07-25       Impact factor: 3.181

9.  Elevated brain harmane (1-methyl-9H-pyrido[3,4-b]indole) in essential tremor cases vs. controls.

Authors:  Elan D Louis; Pam Factor-Litvak; Xinhua Liu; Jean-Paul G Vonsattel; Monika Galecki; Wendy Jiang; Wei Zheng
Journal:  Neurotoxicology       Date:  2013-08-02       Impact factor: 4.294

10.  Elevated blood harmane (1-methyl-9H-pyrido[3,4-b]indole) concentrations in Parkinson's disease.

Authors:  Elan D Louis; Monika Michalec; Wendy Jiang; Pam Factor-Litvak; Wei Zheng
Journal:  Neurotoxicology       Date:  2013-12-01       Impact factor: 4.294

View more
  28 in total

1.  Targeting the vim by direct visualization of the cerebello-thalamo-cortical pathway in 3 T proton density MRI: correlation with focused ultrasound lesioning.

Authors:  Maximiliano Páez-Nova; Roberto Spiegelmann; Simon Korn-Israeli; Zion Zibly; Diego Illera-Rivera; Carmen Daza-Cordoba; Juan Carlos Alcazar-Daza; Ezequiel Garcia-Ballestas
Journal:  Neurosurg Rev       Date:  2022-02-11       Impact factor: 3.042

2.  Epidemiology of Pediatric Essential Tremor in the United States: A Systematic Literature Review from 2010 to 2020.

Authors:  Margaret E Gerbasi; Adi Eldar-Lissai; Kelly E Lyons
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2022-04-19

3.  Perceived embarrassment and caregiver burden in essential tremor caregivers.

Authors:  Sarah Kellner; Sarah Morgan; Jesus Gutierrez; Kathleen Collins; Brittany Rohl; Fanny Migliore; Stephanie Cosentino; Edward D Huey; Elan D Louis; Joan K Monin
Journal:  J Neurol Sci       Date:  2017-11-20       Impact factor: 3.181

4.  Essential tremor-Parkinson's disease: A double whammy.

Authors:  Elan D Louis; Adina Wise; Roy N Alcalay; Ashwini K Rao; Pam Factor-Litvak
Journal:  J Neurol Sci       Date:  2016-04-23       Impact factor: 3.181

5.  STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis.

Authors:  Joshua K Wong; James H Cauraugh; Kwo Wei David Ho; Matthew Broderick; Adolfo Ramirez-Zamora; Leonardo Almeida; Aparna Wagle Shukla; Christina A Wilson; Rob Ma de Bie; Frances M Weaver; Nyeonju Kang; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2018-08-28       Impact factor: 4.891

6.  Quality of life in isolated dystonia: non-motor manifestations matter.

Authors:  Johanna Junker; Brian D Berman; James Hall; Deena W Wahba; Valerie Brandt; Joel S Perlmutter; Joseph Jankovic; Irene A Malaty; Aparna Wagle Shukla; Stephen G Reich; Alberto J Espay; Kevin R Duque; Neepa Patel; Emmanuel Roze; Marie Vidailhet; H A Jinnah; Norbert Brüggemann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-02-09       Impact factor: 13.654

7.  Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients.

Authors:  D Rada; J Seco; E Echevarría; B Tijero; L C Abecia; J C Gómez-Esteban
Journal:  Parkinsons Dis       Date:  2016-04-28

8.  Knowledge about Essential Tremor: A Study of Essential Tremor Families.

Authors:  Ashley D Cristal; Karen P Chen; Nora Cristina Hernandez; Pam Factor-Litvak; Lorraine N Clark; Ruth Ottman; Elan D Louis
Journal:  Front Neurol       Date:  2018-01-26       Impact factor: 4.003

9.  Wearable Peripheral Electrical Stimulation Devices for the Reduction of Essential Tremor: A Review.

Authors:  Alexandra Karamesinis; Roy V Sillitoe; Abbas Z Kouzani
Journal:  IEEE Access       Date:  2021-05-28       Impact factor: 3.367

10.  The Experience of Essential Tremor Caregivers: Burden and Its Correlates.

Authors:  Sarah Morgan; Sarah Kellner; Jesus Gutierrez; Kathleen Collins; Brittany Rohl; Fanny Migliore; Stephanie Cosentino; Edward D Huey; Elan D Louis; Joan K Monin
Journal:  Front Neurol       Date:  2017-08-14       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.